HS-10566
PreclinicalSmall molecule
Jiangsu Hansoh Pharmaceutical Co., Ltd.HS-10566 is one of 2 small molecule programs targeting High-Risk Non-Muscle-Invasive Bladder Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
1
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1 competitor in High-Risk Non-Muscle-Invasive Bladder Cancer
#DrugCompanyPhaseTrials
1Cretostimogene Grenadenorepvec
CCG Oncology, Inc.
Phase 2
HS-10566
Jiangsu Hansoh Pharmaceutical Co., Ltd.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HS-10566. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details